866-997-4948(US-Canada Toll Free)

Follicular Thyroid Cancer Pipeline Review, H2 2012

Published By :

Global Markets Direct

Published Date : Nov 2012

Category :

Cancer

No. of Pages : 27 Pages


Global Markets Directs, \'Follicular Thyroid Cancer Pipeline Review, H2 2012\', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Follicular Thyroid Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Follicular Thyroid Cancer. 

Follicular Thyroid Cancer Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Follicular Thyroid Cancer.
  • A review of the Follicular Thyroid Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Follicular Thyroid Cancer pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Follicular Thyroid Cancer.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Follicular Thyroid Cancer pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents

Table of Contents 2
List of Tables 3
List of Figures 3
Introduction 4
Global Markets Direct Report Coverage 4
Follicular Thyroid Cancer Overview 5
Therapeutics Development 6
An Overview of Pipeline Products for Follicular Thyroid Cancer 6
Follicular Thyroid Cancer Therapeutics under Development by Companies 8
Follicular Thyroid Cancer Therapeutics under Investigation by Universities/Institutes 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Follicular Thyroid Cancer Therapeutics – Products under Development by Companies 11
Follicular Thyroid Cancer Therapeutics – Products under Investigation by Universities/Institutes 12
Companies Involved in Follicular Thyroid Cancer Therapeutics Development 13
Exelixis, Inc. 13
Follicular Thyroid Cancer – Therapeutics Assessment 14
Assessment by Monotherapy Products 14
Assessment by Combination Products 15
Assessment by Route of Administration 16
Assessment by Molecule Type 18
Drug Profiles 20
Alimta + Paclitaxel - Drug Profile 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
thalidomide - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
pioglitazone - Drug Profile 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
Follicular Thyroid Cancer Therapeutics – Drug Profile Updates 23
Follicular Thyroid Cancer Therapeutics - Dormant Products 24
Follicular Thyroid Cancer – Product Development Milestones 25
Featured News & Press Releases 25
Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer 25

Appendix 26
Methodology 26
Coverage 26
Secondary Research 26
Primary Research 26
Expert Panel Validation 26
Contact Us 27
Disclaimer 27

List of Table


Number of Products Under Development for Follicular Thyroid Cancer, H2 2012 6
Products under Development for Follicular Thyroid Cancer Comparative Analysis, H2 2012 7
Number of Products under Development by Companies, H2 2012 8
Number of Products under Investigation by Universities/Institutes, H2 2012 9
Comparative Analysis by Mid Clinical Stage Development, H2 2012 10
Products under Development by Companies, H2 2012 11
Products under Investigation by Universities/Institutes, H2 2012 12
Exelixis, Inc., H2 2012 13
Assessment by Monotherapy Products, H2 2012 14
Assessment by Combination Products, H2 2012 15
Assessment by Stage and Route of Administration, H2 2012 17
Assessment by Stage and Molecule Type, H2 2012 19
Follicular Thyroid Cancer Therapeutics Drug Profile Updates 23
Follicular Thyroid Cancer Therapeutics Dormant Products 24

List of Chart


Number of Products under Development for Follicular Thyroid Cancer, H2 2012 6
Products under Development for Follicular Thyroid Cancer Comparative Analysis, H2 2012 7
Products under Development by Companies, H2 2012 8
Products under Investigation by Universities/Institutes, H2 2012 9
Mid Clinical Stage Products, H2 2012 10
Assessment by Monotherapy Products, H2 2012 14
Assessment by Combination Products, H2 2012 15
Assessment by Route of Administration, H2 2012 16
Assessment by Stage and Route of Administration, H2 2012 17
Assessment by Molecule Type, H2 2012 18
Assessment by Stage and Molecule Type, H2 2012 19

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *